ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.
Sydney Jennings
Advertisement
Editor of Patient Care Online.
Articles by Sydney Jennings
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
Your daily dose of the clinical news you may have missed.
RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.
Your daily dose of the clinical news you may have missed.
At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.
ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.
Your daily dose of the clinical news you may have missed.
ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.
ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.
Your daily dose of the clinical news you may have missed.
Dupilumab is the first targeted treatment for BP to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.
The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.
Your daily dose of the clinical news you may have missed.
RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.
RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.
Your daily dose of the clinical news you may have missed.
The FDA cleared Happy Ring, a wearable device for at-home diagnosis of sleep disorders, enhancing access to vital sleep health solutions.
Your daily dose of the clinical news you may have missed.
Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.
Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.
RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.
EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential
2
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
3
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
4
APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause
5
